Cyient DLM Limited — Investor Meet, 24-04-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance:** For Q4 FY '25, Cyient DLM reported a revenue of ₹4,281 million, marking an 18.3% year-over-year growth. The EBITDA stood at ₹574 million, reflecting a substantial 50.9% increase. The profit for the quarter reached ₹310 million, a 36.5% rise year-on-year, with EBITDA margins at 13.4%, up 290 basis points. However, the standalone revenue was ₹3,403 million, a decline of 5.9% year-on-year. Notably, the strong performance was partly bolstered by one-off tailwinds related to purchase price variance claims.

2. **Future Outlook and Growth Drivers:** Management expressed optimism regarding future strategies focusing on U.S. market expansion amid increasing tariffs favoring local manufacturing. The integration of Altek is now complete, providing new growth opportunities, particularly in the medical and industrial sectors. The company remains positioned to capture a robust pipeline of opportunities, with expectations for conversion into orders in the upcoming year.

3. **Order Book and Operational Updates:** The order backlog as of Q4 stands at ₹1,906 crores, down from previous quarters due to project completions but expected to recover given the anticipated inflow from a strong pipeline. Management identified ongoing discussions with key OEMs and a focus on diversifying the supply chain to mitigate risks.

4. **Analyst Q&A Insights (Detailed):**

- **Revenue and Profitability:** Analysts inquired about the pace of converting the strong pipeline into backlog. Management indicated that while there may be a soft start to FY '26, they expect to see a buildup in orders as key deals are finalized.

- **Market Position and Competitive Landscape:** Questions regarding the competitive threats were addressed as management highlighted the growing interest in U.S. manufacturing capabilities and the strategic importance of having operations both in India and the U.S.

- **Operational Challenges or Risks:** Supply chain concerns were raised, but management reassured that challenges have not yet impacted them severely, though market dynamics remain closely monitored.

- **Capex and Capital Allocation:** Analysts were interested in the capital allocation post-acquisition, with management indicating a focus on leveraging funds for operational growth while maintaining a flexible approach to capital deployment aligned with emerging opportunities.

- **Strategic Priorities and Long-Term Vision:** Conversations highlighted the emphasis on hybrid models for production, combining Indian capabilities with U.S. proximity to clients, thus diversifying risk while enhancing growth potential.

5. **Market or Regulatory Updates:** Discussion surrounding increased U.S. tariffs on Chinese imports presents opportunities for Cyient DLM to attract new customers seeking reliable local manufacturing partners, especially within high-stakes sectors like aerospace and medical technology.

6. **Strategic Focus Areas:** Emphasis on operational efficiency, innovation, and supply chain diversification reveals strategic themes aimed at bolstering resilience and mitigating disruptions, reflecting a proactive management approach to industry challenges.

7. **Investor Insight:** Despite short-term headwinds and a soft start anticipated for FY '26, Cyient DLM’s robust pipeline, successful integration of Altek, and evolving market dynamics indicate strong potential for growth. There appears to be a favorable tilt towards a 'buy' position as the company strategically leverages its enhanced capabilities. The underlying financial strength and responsiveness to market changes signal promising future performance.